AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34889352 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticket to Home (TTH) survey tool before discharge
Number of subjects: 100
Study 34889352 — intervention group
Group type: COMPARATOR
Intervention: Usual care (without TTH survey tool)
Number of subjects: 100
Study 34551215 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi + insulin glulisine
Number of subjects: 40
Study 34551215 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injection therapy
Number of subjects: 40
Study 33788975 — intervention group
Group type: EXPERIMENTAL
Intervention: Active aiTBS
Number of subjects: 50
Study 33788975 — intervention group
Group type: COMPARATOR
Intervention: Sham (Control)
Number of subjects: 50
Study 35804406 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based traditional Chinese medicine massage (2 sessions per week for 10 weeks)
Number of subjects: 300
Study 35804406 — intervention group
Group type: COMPARATOR
Intervention: External Diclofenac Diethylamine Emulgel (3-4 times per day for 10 weeks)
Number of subjects: 300
Study 35804406 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based traditional Chinese medicine massage
Number of subjects: 300
Study 35804406 — intervention group
Group type: COMPARATOR
Intervention: External Diclofenac Diethylamine Emulgel
Number of subjects: 300
Study 33540680 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted cataract surgery (FLACS)
Number of subjects: 130
Study 33540680 — intervention group
Group type: COMPARATOR
Intervention: Conventional cataract surgery
Number of subjects: 130
Study 32403999 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous neuromodulation (PNM)
Number of subjects: 80
Study 32403999 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle technique (without electrical stimulation)
Number of subjects: 80
Study 32403999 — intervention group
Group type: COMPARATOR
Intervention: Neurodynamic sciatic sliding technique
Number of subjects: 80
Study 32403999 — intervention group
Group type: COMPARATOR
Intervention: Hamstring stretching
Number of subjects: 80
Study 32697618 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 486
Study 32697618 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 486
Study 32697618 — intervention group
Group type: COMPARATOR
Intervention: Control (no medication)
Number of subjects: 486
Study 33832116 — intervention group
Group type: EXPERIMENTAL
Intervention: Chaihu Guizhi decoction (CGD), administered twice a day for 7 days after TACE.
Number of subjects: 0
Study 33832116 — intervention group
Group type: COMPARATOR
Intervention: CGD simulations (placebo), administered twice a day for 7 days after TACE.
Number of subjects: 0
Study 32164440 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel community-based enhanced care intervention
Number of subjects: 60
Study 35486445 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet (LCD)
Number of subjects: 45
Study 35486445 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study 35486445 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight change
Number of subjects: 45
Study 35486445 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in zonulin
Number of subjects: 45
Study 34619438 — intervention group
Group type: EXPERIMENTAL
Intervention: ND0612 (levodopa/carbidopa) infusion
Number of subjects: 16
Study 34619438 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion + standard of care (SoC)
Number of subjects: 16
Study 34619438 — intervention group
Group type: EXPERIMENTAL
Intervention: ND0612 plus oral entacapone
Number of subjects: 16
Study 34619438 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC) levodopa/carbidopa
Number of subjects: 16
Study 35550468 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinomenine (zhengqing fengtongning sustained-release tablets) administered for 12 weeks along with febuxostat (40 mg/d) and anti-inflammatory prophylaxis therapy.
Number of subjects: 210
Study 35550468 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinomenine (zhengqing fengtongning sustained-release tablets) administered for 12 weeks.
Number of subjects: 210
Study 35550468 — intervention group
Group type: COMPARATOR
Intervention: Colchicine placebo administered for 12 weeks along with febuxostat (40 mg/d) and anti-inflammatory prophylaxis therapy.
Number of subjects: 210
Study 35550468 — intervention group
Group type: COMPARATOR
Intervention: Colchicine administered for 12 weeks.
Number of subjects: 210
Study 32966919 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (300 IU/kg up to a maximum of 6000 IU daily)
Number of subjects: 43
Study 32966919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 34838475 — intervention group
Group type: EXPERIMENTAL
Intervention: EWS + MTM
Number of subjects: 188
Study 34838475 — intervention group
Group type: EXPERIMENTAL
Intervention: EWS
Number of subjects: 188
Study 34838475 — intervention group
Group type: COMPARATOR
Intervention: SS (control)
Number of subjects: 188
Study 33989455 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of personality disorder traits
Number of subjects: 69
Study 33989455 — intervention group
Group type: COMPARATOR
Intervention: Lower levels of personality disorder traits
Number of subjects: 69
Study 33989455 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PD
Number of subjects: 69
Study 33989455 — intervention group
Group type: COMPARATOR
Intervention: Patients without PD
Number of subjects: 69
Study 32945536 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alcohol administration
Number of subjects: 27
Study 32945536 — intervention group
Group type: COMPARATOR
Intervention: Placebo (water cues)
Number of subjects: 27
Study 35263457 — intervention group
Group type: EXPERIMENTAL
Intervention: Fertile Chip
Number of subjects: 128
Study 35263457 — intervention group
Group type: COMPARATOR
Intervention: Traditional swim-up procedures
Number of subjects: 128
Study 32807873 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet-filtering IOL (UVF-IOL)
Number of subjects: 7
Study 32807873 — intervention group
Group type: COMPARATOR
Intervention: Blue-light-filtering IOL (BF-IOL)
Number of subjects: 7
Study 33096333 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored internet-based intervention (IMI) program
Number of subjects: 360
Study 33096333 — intervention group
Group type: COMPARATOR
Intervention: Enhanced treatment as usual
Number of subjects: 360
Study 32001798 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab plus lenalidomide/dexamethasone (D-Rd)
Number of subjects: 569
Study 36305511 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled acetaminophen, gabapentin, ketorolac, and as-needed opioids (Experimental group)
Number of subjects: 31
Study 36305511 — intervention group
Group type: COMPARATOR
Intervention: Scheduled acetaminophen and as-needed opioids (Control group)
Number of subjects: 31
Study 36305511 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled acetaminophen, gabapentin, ketorolac, a regional nerve block at the free tissue donor site, scheduled acetaminophen and as-needed opioids (Experimental group)
Number of subjects: 31
Study 36305511 — intervention group
Group type: COMPARATOR
Intervention: Scheduled acetaminophen and as-needed opioids (Arm A)
Number of subjects: 31
Study 36305511 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled gabapentin, ketorolac, a regional nerve block at the free tissue donor site, scheduled acetaminophen and as-needed opioids (Arm B)
Number of subjects: 31
Study 36305511 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 36305511 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 31
Study 36305511 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 31
Study 35034635 — intervention group
Group type: EXPERIMENTAL
Intervention: Information nudges
Number of subjects: 11775
Study 35034635 — intervention group
Group type: EXPERIMENTAL
Intervention: Position nudges
Number of subjects: 11775
Study 35034635 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined nudges
Number of subjects: 11775
Study 35034635 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 11775
Study 32777606 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone/Buprenorphine (NTX/BUP)
Number of subjects: 0
Study 32777606 — intervention group
Group type: COMPARATOR
Intervention: Placebo-Naltrexone/Buprenorphine (PBO-N/BUP)
Number of subjects: 0
Study 34998804 — intervention group
Group type: EXPERIMENTAL
Intervention: TD‐CBT+TAU
Number of subjects: 1061
Study 34998804 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 1061
Study 34538072 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib (250 mg or 300 mg) taken orally once on days 1-5 and days 8-12 of a 3-week cycle
Number of subjects: 69
Study 34538072 — intervention group
Group type: COMPARATOR
Intervention: Active Monitoring (AM)
Number of subjects: 69
Study 34538072 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib (250 mg or 300 mg)
Number of subjects: 69
Study 34538072 — intervention group
Group type: EXPERIMENTAL
Intervention: Adavosertib
Number of subjects: 69
Study 35439303 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg twice daily for 3 weeks, followed by 20 mg daily for an intended duration of 3 months
Number of subjects: 100
Study 35439303 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 100
Study 32188447 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive plate osteosynthesis (MIPO) combined with curved incision on the anterior area of ankle
Number of subjects: 17
Study 34669009 — intervention group
Group type: EXPERIMENTAL
Intervention: + DSS (Decision Support System)
Number of subjects: 194
Study 34669009 — intervention group
Group type: COMPARATOR
Intervention: - DSS (no Decision Support System)
Number of subjects: 194
Study 34669009 — intervention group
Group type: EXPERIMENTAL
Intervention: Standalone DSS (without clinician's final decision)
Number of subjects: 194
Study 33234138 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol therapy for women > 50 years
Number of subjects: 37086
Study 33234138 — intervention group
Group type: COMPARATOR
Intervention: No estradiol therapy for women > 50 years
Number of subjects: 37086
Study 33234138 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol therapy for women 15–49 years
Number of subjects: 37086
Study 33234138 — intervention group
Group type: COMPARATOR
Intervention: No estradiol therapy for women 15–49 years
Number of subjects: 37086
Study 35081360 — intervention group
Group type: EXPERIMENTAL
Intervention: Best Practice Advisory (BPA) added to Atrial Fibrillation Decision Support Tool (AFDST)
Number of subjects: 800
Study 35081360 — intervention group
Group type: COMPARATOR
Intervention: Usual care with AFDST available
Number of subjects: 800
Study 34886081 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense Endurance Training (IET)
Number of subjects: 16
Study 34886081 — intervention group
Group type: COMPARATOR
Intervention: Moderate Endurance Training (MET)
Number of subjects: 16
Study 32718319 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralized invitations sent from a central authority involving the attending physician
Number of subjects: 123
Study 32718319 — intervention group
Group type: EXPERIMENTAL
Intervention: Providing attending physicians with lists of unscreened women among their patients
Number of subjects: 123
Study 32718319 — intervention group
Group type: COMPARATOR
Intervention: Targeting women over 50 years old
Number of subjects: 123
Study 32718319 — intervention group
Group type: COMPARATOR
Intervention: Targeting women living in deprived areas
Number of subjects: 123
Study 32718319 — intervention group
Group type: EXPERIMENTAL
Intervention: Allowing nurses to perform Pap smears
Number of subjects: 123
Study 32718319 — intervention group
Group type: COMPARATOR
Intervention: Self-collected oncogenic papillomavirus testing
Number of subjects: 123
Study 35270403 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based multi-approach treatment (MindBlooming) consisting of psychoeducational videos and exercises over 7 weeks
Number of subjects: 0
Study 35270403 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based multi-approach treatment (MindBlooming)
Number of subjects: 0
Study 33645253 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperglycemic clamp protocol with glucose targets of 200 mg/dL and >450 mg/dL, utilizing a centralized spreadsheet-based algorithm for dextrose infusion rates.
Number of subjects: 0
Study 33645253 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment during hyperglycemic clamps.
Number of subjects: 0
Study 32666333 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab every 6 weeks
Number of subjects: 191
Study 32666333 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab every 8 weeks
Number of subjects: 191
Study 32666333 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab every 4 weeks
Number of subjects: 191
Study 35132025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral pectointercostal fascial plane block with 20 ml of 0.25% bupivacaine plus epinephrine (5 mcg/mL)
Number of subjects: 70
Study 35132025 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral pectointercostal fascial plane block
Number of subjects: 70
Study 35132025 — intervention group
Group type: COMPARATOR
Intervention: Control group (dry needling)
Number of subjects: 70
Study 34238659 — intervention group
Group type: EXPERIMENTAL
Intervention: Three‐component lifestyle intervention with short message service (SMS+)
Number of subjects: 183
Study 34238659 — intervention group
Group type: EXPERIMENTAL
Intervention: Three‐component lifestyle intervention without SMS (SMS–)
Number of subjects: 183
Study 34238659 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 183
Study 34238659 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (general effect)
Number of subjects: 183
Study 34238659 — intervention group
Group type: COMPARATOR
Intervention: Comparison of SMS– group to CAU
Number of subjects: 183
Study 35101109 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole systems strengthening package including community men's and women's groups, Partnership Defined Quality Scorecard, healthcare worker training, mentorship, and provision of basic essential equipment and commodities.
Number of subjects: 4480
Study 35101109 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole systems strengthening package
Number of subjects: 4480
Study 34992552 — intervention group
Group type: EXPERIMENTAL
Intervention: E-PAtS and usual practice
Number of subjects: 74
Study 34992552 — intervention group
Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 74
Study 36051506 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps isometric exercises in knee extension (n=14)
Number of subjects: 30
Study 36051506 — intervention group
Group type: COMPARATOR
Intervention: Quadriceps isometric exercises in knee flexion (n=15)
Number of subjects: 30
Study 33026490 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga therapy (8 weekly sessions of 60 min each)
Number of subjects: 173
Study 33026490 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (CG)
Number of subjects: 173
Study 36417955 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (transfusion of RBCs sufficient to raise hemoglobin to at least 10 g/dL)
Number of subjects: 3500
Study 36417955 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (transfusion of RBCs if hemoglobin falls below 8 g/dL or for persistent angina despite medical therapy)
Number of subjects: 3500
Study 33608319 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose tamoxifen
Number of subjects: 0
Study 32630188 — intervention group
Group type: EXPERIMENTAL
Intervention: Ai Chi aquatic therapy
Number of subjects: 40
Study 32630188 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (alternating dry-land therapy and Ai Chi aquatic therapy)
Number of subjects: 40
Study 32630188 — intervention group
Group type: COMPARATOR
Intervention: Dry-land therapy (control group)
Number of subjects: 40
Study 35661111 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective food response inhibition training
Number of subjects: 90
Study 35661111 — intervention group
Group type: COMPARATOR
Intervention: Sham training following binge memory reactivation
Number of subjects: 90
Study 35661111 — intervention group
Group type: COMPARATOR
Intervention: Training without binge memory reactivation
Number of subjects: 90
Study 33845449 — intervention group
Group type: EXPERIMENTAL
Intervention: Day case tonsillectomy
Number of subjects: 300
Study 33845449 — intervention group
Group type: COMPARATOR
Intervention: Inpatient tonsillectomy
Number of subjects: 300
Study 33043883 — intervention group
Group type: EXPERIMENTAL
Intervention: DMT
Number of subjects: 0
Study 33043883 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 0
Study 36244877 — intervention group
Group type: EXPERIMENTAL
Intervention: Food stress (not having enough money for food, not having enough time for cooking or shopping)
Number of subjects: 192
Study 36244877 — intervention group
Group type: EXPERIMENTAL
Intervention: Food stress (inadequate food access, being on a special diet)
Number of subjects: 192
Study 36244877 — intervention group
Group type: EXPERIMENTAL
Intervention: Food stress (not having enough money for food, being on a special diet)
Number of subjects: 192
Study 35304705 — intervention group
Group type: EXPERIMENTAL
Intervention: Antrum Resection (AR)
Number of subjects: 109
Study 35304705 — intervention group
Group type: COMPARATOR
Intervention: Antrum Preservation (AP)
Number of subjects: 109
Study 33023894 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with sodium nitrite (40 mg twice daily) and isoquercetin (225 mg once daily) for 12 weeks
Number of subjects: 70
Study 33023894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 33023894 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with sodium nitrite and isoquercetin
Number of subjects: 70
Study 32998993 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinding of outcome assessors
Number of subjects: 63
Study 32998993 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinding of participants
Number of subjects: 63
Study 32998993 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinding of data managers
Number of subjects: 63
Study 32998993 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinding of statisticians
Number of subjects: 63
Study 32998993 — intervention group
Group type: EXPERIMENTAL
Intervention: Rejection of the null hypothesis on the primary outcome(s)
Number of subjects: 63
Study 32998993 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of potential bias risk from lack of blinding
Number of subjects: 63
Study 33109661 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebuliser with data recording and transfer capability, linked to a software platform, and strategies to support adherence to nebulised treatments facilitated by interventionists over 5 months (+/‐ 1 month)
Number of subjects: 14
Study 33109661 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventionists conducting review visits
Number of subjects: 14
Study 33109661 — intervention group
Group type: EXPERIMENTAL
Intervention: Process evaluation of adherence support intervention
Number of subjects: 14
Study 35131974 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinized saline (10-100 U/mL; CVAD-type dependent)
Number of subjects: 61
Study 35131974 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 61
Study 34898455 — intervention group
Group type: EXPERIMENTAL
Intervention: Video consultations
Number of subjects: 233
Study 34898455 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face consultations
Number of subjects: 233
Study 32955293 — intervention group
Group type: EXPERIMENTAL
Intervention: Awe walk intervention (15-min outdoor walks for 8 weeks)
Number of subjects: 60
Study 32955293 — intervention group
Group type: COMPARATOR
Intervention: Control walk group (15-min outdoor walks for 8 weeks)
Number of subjects: 60
Study 32955293 — intervention group
Group type: EXPERIMENTAL
Intervention: Awe walk intervention
Number of subjects: 60
Study 32955293 — intervention group
Group type: COMPARATOR
Intervention: Control walk group
Number of subjects: 60
Study 34310411 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening Clinical Breast Examination (CBE)
Number of subjects: 0
Study 34310411 — intervention group
Group type: COMPARATOR
Intervention: Modern screening mammography
Number of subjects: 0
Study 32487250 — intervention group
Group type: EXPERIMENTAL
Intervention: PST-IPV (Problem Solving Therapy tailored for IPV)
Number of subjects: 75
Study 32487250 — intervention group
Group type: COMPARATOR
Intervention: Standard PST (Problem Solving Therapy)
Number of subjects: 75
Study 32487250 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (information about sources of support)
Number of subjects: 75
Study 34009787 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical race position (RP)
Number of subjects: 1
Study 34009787 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified upright position (UP)
Number of subjects: 1
Study 34009787 — intervention group
Group type: COMPARATOR
Intervention: Traditional measures of vascular responsiveness
Number of subjects: 1
Study 33606090 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg body mass)
Number of subjects: 20
Study 33606090 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 20
Study 32731812 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch‐Up (ABC) intervention
Number of subjects: 68
Study 32731812 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 68
Study 32731812 — intervention group
Group type: EXPERIMENTAL
Intervention: ABC intervention
Number of subjects: 68
Study 34716213 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg daily for 8 weeks
Number of subjects: 40
Study 34716213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 35141484 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial extracorporeal shock wave therapy (rESWT) - 25 patients, 3 sessions (once per week, 1.8 bar pneumatic pressure, 10 Hz frequency, 2,000 pulses)
Number of subjects: 50